Margulis, Vitaly <br/><br/>
Cytoreductive nephrectomy in the era of targeted molecular agents: is it time to consider presurgical systemic therapy?  [electronic resource] 

 -  European urology  Sep 2008 
 - 489-92 p.  digital 
<br/><br/> Publication Type: Editorial 
<br/><br/><label>ISSN: </label>0302-2838 
<br/><br/><label>Standard No.: </label>10.1016/j.eururo.2007.12.041  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Angiogenesis Inhibitors--therapeutic use<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Bevacizumab<br/>Carcinoma, Renal Cell--pathology<br/>Clinical Trials as Topic<br/>Combined Modality Therapy<br/>Humans<br/>Indoles--therapeutic use<br/>Interferon-alpha--therapeutic use<br/>Kidney Neoplasms--pathology<br/>Nephrectomy--methods<br/>Protein Kinases--therapeutic use<br/>Pyrazoles--therapeutic use<br/>Pyrimidines--therapeutic use<br/>Pyrroles--therapeutic use<br/>Sunitinib<br/>Survival Analysis<br/>TOR Serine-Threonine Kinases<br/>Vascular Endothelial Growth Factor A--antagonists & inhibitors